ProBioGen is expected to contribute producer cell line development and process engineering for one of Virdante’s proprietary therapeutic proteins.
Virdante Pharmaceuticals claimed that the protein products are unique in that they incorporate Virdante’s proprietary ‘Sialic Switch’ technology that improves the anti-inflammatory properties of an antibody for autoimmune and inflammatory diseases.
Virdante Pharmaceuticals selected ProBioGen for its expertise in developing royalty-free pharmaceutical cell lines and robust, economical processes for GMP-manufacturing.
Volker Sandig, chief scientific officer of ProBioGen, said: “We are highly impressed by Virdante´s products and strategies and their compelling scientific rationale to improve human proteins. We are excited to contribute our knowledge in harnessing the cellular machinery to maximize productivity for this ambitious project.”